Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Purine compounds as Trk kinase inhibitors

A compound, purine technology, applied in the field of purine compounds

Active Publication Date: 2019-09-20
南京雷正医药科技有限公司
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] The problem to be solved by the invention: In order to overcome the problems of insufficient stability and activity in the prior art and meet the growing clinical needs, the present invention provides a novel substituted purine compound as a Trk kinase inhibitor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Purine compounds as Trk kinase inhibitors
  • Purine compounds as Trk kinase inhibitors
  • Purine compounds as Trk kinase inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0096] The preparation of embodiment 1 intermediate:

[0097] Preparation of 2-chloro-N-(4-fluorobenzyl)-9H-purin-6-amine:

[0098] The structural formula is as follows:

[0099] Add n-butanol (50mL) and 2,4-dichloropyrimidine (5g, 26.7mmol) into an eggplant-shaped bottle (250mL), stir to dissolve, then slowly add p-fluorobenzylamine (3.4g, 27mmol) and triethyl Amine (3.4g, 33.6mmol) was heated to 110°C for 3h. It was detected by TLC that the reaction was complete, cooled to 20° C., a solid precipitated out, filtered with suction, washed with n-butanol (5 mL), and dried to obtain a white solid product (5.5 g, yield 75%).

[0100] Preparation of 2-chloro-N-(4-fluorobenzyl)-9-isopropyl-9H-purin-6-amine (intermediate A1):

[0101] The structural formula is as follows:

[0102] Add DMSO (10mL) and 2-chloro-N-(4-fluorobenzyl)-9H-purin-6-amine (2g, 7.2mmol) into an eggplant-shaped flask (250mL), stir to dissolve, and store at 18-20°C Potassium carbonate (3.5 g, 25.3 mmol) a...

Embodiment 2

[0121] Example 2 Preparation of (S)-2-((6-(4-fluorobenzoyl)-9-isopropyl-9H-purin-2-ol) butanone-1-ol

[0122]

[0123] Add intermediate A1 (1.2g, 3.8mmol) and (R)-2-amino-1-butanol (3mL) into an eggplant-shaped flask (25mL), under nitrogen protection, heat to 160°C for 8h, and TLC detects that the reaction is complete , cooled to room temperature, added water (20 mL), extracted with ethyl acetate (20 mL×4), washed the organic layer with 50°C warm water (30 mL×2), dried over sodium sulfate, and evaporated most of the solvent under reduced pressure. Ethyl acetate (10 mL) was added to the residual liquid, crystals were precipitated, and white crystals (1 g, 70%) were obtained by filtration.

[0124] 1 H-NMR (400MHz, CDCl 3 )δ: 7.48(d,J=2.0Hz,1H),7.36–7.29(m,2H),7.04–6.97(m,2H),6.01(s,1H),5.04(s,1H),4.89(d ,J=6.1Hz,1H),4.73(s,2H),4.60(p,J=6.8Hz,1H),3.85-3.93(m,1H),3.82(dd,J=10.7,2.6Hz,1H) ,3.63(dd,J=10.7,7.7Hz,1H),1.85(s,1H),1.64–1.57(m,1H),1.53(d,J=6.7Hz,6H),0.97-0.08(m,3H...

Embodiment 3

[0125] Example 3 Preparation of 2-((6-(4-fluorophenyl)amino)-9-isopropyl-9H-purin-2-yl)amino)-2-phenethyl 1-ol

[0126] Synthesis was carried out in the same manner as that of Compound 1 except that DL-phenylglycinol was used instead of (R)-2-amino-1-butanol. The structural formula is as follows:

[0127]

[0128] 1 H-NMR (400MHz, DMSO-d 6 )δ: 8.82(s, 1H), 8.29(s, 1H), 7.76(s, 1H), 7.32-7.43(m, 3H), 7.24(t, J=7.5Hz, 1H), 7.11-7.19(m ,2H),7.05(s,1H),6.61(d,J=7.5Hz,0H),4.71–4.64(m,1H),4.61(d,J=6.2Hz,2H),4.54–4.40(m, 1H), 3.69–3.57(m, 1H), 1.50(d, J=6.8Hz, 6H), 1.41(d, J=6.7Hz, 2H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses purine compounds as Trk kinase inhibitors, and belongs to the field of chemical medicines. The purine compounds disclosed by the invention are shown in a general formula (I), have good inhibitory activity on Trk-family protein tyrosine kinase, can be used for treating cancers, pains, inflammation, neurodegenerative diseases, Trypanosome cruzi infection or osteolysis diseases of mammals, and has a wide application prospect.

Description

technical field [0001] The invention belongs to the field of chemical medicine, in particular to purine compounds as Trk kinase inhibitors. Background technique [0002] The occurrence of malignant tumors is caused by a series of gene abnormalities, including the inactivation of tumor suppressor genes and the activation of proto-oncogenes. Cancer cells grow vigorously, showing relatively endless growth, which is not in harmony with the normal metabolism of the human body, seriously affects the normal functions of various organs of the human body, destroys the normal tissue structure of the human body, and is a disease that seriously endangers human life and health. The development of small molecule kinase inhibitors as potential cancer therapies is currently an area of ​​interest, as mutations and gene fusions of certain Trks and their controlled counterparts are associated with uncontrolled tumorigenesis and proliferation . [0003] Tropomyosin-related kinase (Trk) is a k...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D473/16A61P35/00A61P19/02A61P29/00A61P25/28A61P19/08A61P33/02A61K31/5377A61K31/52
CPCA61P19/02A61P19/08A61P25/28A61P29/00A61P33/02A61P35/00C07D473/16Y02A50/30
Inventor 范为正杨加举范文华刘彦唐春雷
Owner 南京雷正医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com